Dose-limiting, adverse event–associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial

by Abraham, W.T, Aleong, R., Anand, I.S, Bristow, M.R, Carroll, I.A, Connolly, S.J, Dufton, C., Healey, J.S, Huebler, S.P, Marshall, D., O'Connor, C.M, Piccini, J.P, Rienstra, M., Sauer, W.H, van Veldhuisen, D.J, White, M., Wilton, S.B
Published 2022